Provided By GlobeNewswire
Last update: Sep 9, 2024
DOYLESTOWN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Oren Gilad Ph.D, President and Chief Executive Officer, will provide a corporate update at the H.C. Wainwright 26th Annual Global Investment Conference to take place September 9-11, 2024 in New York, NY. Details are as follows:
NASDAQ:APRE (8/1/2025, 4:18:34 PM)
1.66
-0.04 (-2.35%)
Find more stocks in the Stock Screener